2-anilino-6-methyl-nicotinic acid | 54530-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-anilino-6-methyl-nicotinic acid
• 英文别名: 2-Anilino-6-methylpyridine-3-carboxylic acid
• CAS: 54530-68-6
• 化学式: C₁₃H₁₂N₂O₂
• 分子量: 228.25
• InChiKey: RXARQPJWGRWGDI-UHFFFAOYSA-N

物化性质

• 熔点：
  156-158 °C(Solv: benzene (71-43-2))
• 沸点：
  391.8±42.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-anilino-6-methyl-nicotinic acid 在 三乙胺 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 24.0h， 生成 Methyl 2-anilino-6-methylpyridine-3-carboxylate
  参考文献：
  名称：

  Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release

  摘要：

  A novel class of antiallergy agents, the substituted 1,8-naphthyridin-2(1H)-ones, is described. The present compounds are orally active, potent inhibitors of allergic and nonallergic bronchospasm in animal models. Structure-activity studies of the lead compound in this series, 1-phenyl-3-n-butyl-4-hydroxynaphthyridin-2(1H)-one (11), identified three compounds of interest, 1-phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (12), 1-(3'-chlorophenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H )-one (87), and 1-(3'-methoxyphenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1 H)-one (89). The mechanism of antiallergy activity may involve inhibition of the release of the sulfidopeptide leukotrienes. 1-Phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one, Sch 33303 (12), was selected for preclinical development as an antiallergy agent.

  DOI：

  10.1021/jm00119a010
• 作为产物：
  描述：

  2-phenylamino-6-methylnicotinonitrile 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以984 mg的产率得到2-anilino-6-methyl-nicotinic acid
  参考文献：
  名称：

  [EN] METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
  [FR] INHIBITEUR DE MÉTHIONINE ADÉNOSYLTRANSFÉRASE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用

  摘要：

  一种可作为MAT2a抑制剂的式(I)化合物，包含此类化合物的药物组合物、此类化合物用于制备治疗如癌症的药物的用途以及制备此类化合物的方法。

  公开号：

  WO2022053022A1

文献信息

• Synthesis of Tribenzo[<i>b</i>,<i>d</i>,<i>f</i>]azepines via Cascade π-Extended Decarboxylative Annulation Involving Cyclic Diaryliodonium Salts
  作者：Tao Hu、Zenghui Ye、Kai Zhu、Kai Xu、Yanqi Wu、Fengzhi Zhang

  DOI：10.1021/acs.orglett.9b04269

  日期：2020.1.17

  step-economical protocol is that the carboxylic acid functionality was employed as both a traceless directing group for the N-H activation/arylation and a functional handle for the tandem π-extended decarboxylative annulation.

  在Pd（II）催化下，以易得的2-氨基苯甲酸和环状高价二芳基碘鎓试剂为起始原料，可以有效地制备各种官能化的三苯并[b，d，f] pine子。这种经济实惠的步骤的关键在于，羧酸官能团既用作NH活化/芳基化的无痕导向基团，又用作串联π扩展的脱羧环化的官能团。
• [EN] METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF<br/>[FR] INHIBITEUR DE MÉTHIONINE ADÉNOSYLTRANSFÉRASE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
  申请人：SCINNOHUB PHARMACEUTICAL CO LTD

  公开号：WO2022053022A1

  公开（公告）日：2022-03-17

  一种可作为MAT2a抑制剂的式(I)化合物，包含此类化合物的药物组合物、此类化合物用于制备治疗如癌症的药物的用途以及制备此类化合物的方法。
• 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE
  申请人：Price Stephen

  公开号：US20100004269A1

  公开（公告）日：2010-01-07

  The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的式I的咪唑吡啶，更具体地涉及抑制MEK激酶活性的咪唑吡啶。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增殖性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• AMINOMETHYL QUINOLONE COMPOUNDS
  申请人：Bilotta Joseph A.

  公开号：US20130018043A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  本发明涉及JNK抑制剂及其相应的方法、配方和组合物，用于抑制JNK并治疗JNK介导的疾病。本申请公开了JNK抑制剂，如下式I所述：其中变量如本文所定义。本文所披露的化合物和组合物，有利于调节JNK的活性并治疗与JNK活性相关的疾病。本文披露了用所述化合物抑制JNK和治疗JNK介导的疾病的方法和配方，以及制备上述化合物和相应组合物的过程。
• Discovery of a novel series of 4-quinolone JNK inhibitors
  作者：Leyi Gong、Yun-Chou Tan、Genevieve Boice、Sarah Abbot、Kristen McCaleb、Pravin Iyer、Fengrong Zuo、Joseph Dal Porto、Brian Wong、Sue Jin、Alice Chang、Patricia Tran、Gary Hsieh、Linghao Niu、Ada Shao、Deborah Reuter、Christine M. Lukacs、R. Ursula Kammlott、Andreas Kuglstatter、David Goldstein

  DOI：10.1016/j.bmcl.2012.10.066

  日期：2012.12

  A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC50 of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model. Published by Elsevier Ltd.